Regeneron Pharmaceuticals Ownership


USD 613.61  1.35  0.22%   

Some institutional investors establish a significant position in stocks such as Regeneron Pharmaceuticals in order to find ways to drive up its value. Retail investors, on the other hand, need to know that institutional holders can own millions of shares of Regeneron Pharmaceuticals, and when they decide to sell, the stock will often sell-off, which may instantly impact shareholders' value. So, traders who get in early or near the beginning of the institutional investor's buying cycle could potentially generate profits. Additionally, take a look at Your Equity Center.
Regeneron Pharmaceuticals Accounts Payable Turnover is quite stable at the moment as compared to the past year. The company's current value of Accounts Payable Turnover is estimated at 34.63. Accrued Expenses Turnover is expected to rise to 11.88 this year, although the value of PPandE Turnover will most likely fall to 3.80.
Regeneron Pharmaceuticals owns a total of one hundred eight million thirty thousand outstanding shares. The majority of Regeneron Pharmaceuticals outstanding shares are owned by third-party entities. These institutional holders are usually referred to as non-private investors looking to secure positions in Regeneron Pharmaceuticals to benefit from reduced commissions. Consequently, institutional investors are subject to a different set of regulations than regular investors in Regeneron Pharmaceuticals. Please pay attention to any change in the institutional holdings of Regeneron Pharmaceuticals as this could imply that something significant has changed or about to change at the company. Please note that no matter how much assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Regeneron Stock Ownership Analysis

About 88.0% of the company shares are owned by institutional investors. The book value of Regeneron Pharmaceuticals was at this time reported as 185.41. The company recorded earning per share (EPS) of 69.88. Regeneron Pharmaceuticals had not issued any dividends in recent years. Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10492 people. To find out more about Regeneron Pharmaceuticals contact Leonard Schleifer at 914 847-7000 or learn more at

Regeneron Stock Institutional Investors

Have you ever been surprised when a price of an equity instrument such as Regeneron Pharmaceuticals is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Regeneron Pharmaceuticals backward and forwards among themselves. Regeneron Pharmaceuticals' institutional investor refers to the entity that pools money to purchase Regeneron Pharmaceuticals' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
Security TypeSharesValue
Sumitomo Mitsui Trust Holdings IncCommon Shares399.3 K236.1 M
Candriam ScaCommon Shares372.8 K220.4 M
New York State Common Retirement FundCommon Shares194.3 K114.9 M
Handelsbanken Fonder AbCommon Shares194.3 K114.9 M
Dekabank Deutsche GirozentraleCommon Shares171.2 K102 M
Mcdonald Capital Investors IncCommon Shares164.1 K97 M
Russell Investments Group LtdCommon Shares160.6 K95.2 M
Note, although Regeneron Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Regeneron Pharmaceuticals Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Regeneron Pharmaceuticals insiders, such as employees or executives, is commonly permitted as long as it does not rely on Regeneron Pharmaceuticals' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Regeneron Pharmaceuticals insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Marion McCourt few days ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Marion McCourt over a month ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Marion McCourt over two months ago via Macroaxis 
Exercise or conversion by Marion McCourt of 1100 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Murphy Andrew J over two months ago via Macroaxis 
Sale by Murphy Andrew J of tradable shares of Regeneron Pharmaceuticals
Murphy Andrew J over two months ago via Macroaxis 
Sale by Murphy Andrew J of 352 shares of Regeneron Pharmaceuticals
Murphy Andrew J over three months ago via Macroaxis 
Sale by Murphy Andrew J of 465 shares of Regeneron Pharmaceuticals
Christopher Fenimore over three months ago via Macroaxis 
Exercise or conversion by Christopher Fenimore of 2450 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Leonard Schleifer over three months ago via Macroaxis 
Regeneron Pharmaceuticals exotic insider transaction detected
Robert Landry over three months ago via Macroaxis 
Exercise or conversion by Robert Landry of 1500 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Michael Brown over three months ago via Macroaxis 
Exercise or conversion by Michael Brown of 408 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Robert Landry over three months ago via Macroaxis 
Exercise or conversion by Robert Landry of 400 shares of Regeneron Pharmaceuticals subject to Rule 16b-3
Huda Zoghbi over three months ago via Macroaxis 
Exercise or conversion by Huda Zoghbi of 2000 shares of Regeneron Pharmaceuticals subject to Rule 16b-3

Regeneron Pharmaceuticals Outstanding Bonds

Regeneron Pharmaceuticals issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Regeneron Pharmaceuticals uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Regeneron bonds can be classified according to their maturity, which is the date when Regeneron Pharmaceuticals has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Regeneron Pharmaceuticals without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Price Ceiling Movement Now


Price Ceiling Movement

Calculate and plot Price Ceiling Movement for different equity instruments
All  Next Launch Module

Currently Active Assets on Macroaxis

Additionally, take a look at Your Equity Center. Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Watchlist Optimization
Optimize watchlists to build efficient portfolio or rebalance existing positions based on mean-variance optimization algorithm
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Money Managers
Screen money managers from public funds and ETFs managed around the world
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Money Flow Index
Determine momentum by analyzing Money Flow Index and other technical indicators
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth YOY
Market Capitalization
65.7 B
Quarterly Revenue Growth YOY
Return On Assets
Return On Equity
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine Regeneron Pharmaceuticals value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.